Please assess the completion status of the following clinical trial:

Trial Title: Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 1 diabetes (according to American Diabetes Association \[ADA\] criteria) within the 8 weeks prior to study entry~* Weigh at least 25 kg (55 lbs)~* Insulin autoantibodies assessed within 10 days of any insulin use OR anti-glutamic acid decarboxylase (GAD) autoantibodies OR anti-ICA512/IA-2 autoantibodies~* Subjects or guardian(s) willing to provide informed consent~Exclusion Criteria:~* Prior participation in a clinical trial that could potentially affect diabetes condition or immunologic status~* Participation in another investigational clinical trial within the 6 weeks prior to study entry~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Anti-CD3 mAb Plus Diabetes Standard of Care Treatment (Type: EXPERIMENTAL): Subjects receive 1.) a 14-day course of anti-CD3 monoclonal antibody (mAb) intravenously (IV) comprised of daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 days of 826 µg/m2 \[Cycle 1\] and, when eligible per protocol, receipt of a second 14-day course after a 12-month interval (at month 13)\[Cycle 2\]. Note: Prior to May 2007, the course of IV daily doses of anti-CD3 mAb were: 57 µg/m2, 115 µg/m2, 230 µg/m2, 460 µg/m2, and 10 days of 919 µg/m2 and, when eligible per protocol, a second course after a 12-month interval (at month 13). 2.) and intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization.
- Diabetes Standard of Care Treatment (Type: ACTIVE_COMPARATOR): Subjects receive intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).